drugset / Trial / NCT05665062
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
Timeline
- Start
- 2023-04-23
- Primary completion
- 2028-06-24
- Completion
- 2041-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STK-009 | Protein / enzyme biologic | — | Subcutaneous |
| Subject | SYNCAR-001 | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |